Cocrystal Pharma, Inc.

19805 N. Creek Parkway

Bothell, WA 98011

 

March 20, 2019

 

VIA EMAIL: [ccat@allianceg.com]

Alliance Global Partners /A.G.P

590 Madison Avenue, 36th Floor

New York, New York 10022

 

RE: Amendment and Submission of Equity Distribution Agreement

 

Ladies and Gentlemen:

 

Reference is made to the Equity Distribution Agreement entered into with you and certain other broker-dealers on July 19, 2018 (the “Agreement”). In connection with the terminating of the Agreement with Barrington Research Associates, Inc. (“Barrington”) and suspending the Agreement as to Alliance Global Partners (“AGP”), Cocrystal Pharma, Inc. (the “Company”) and AGP each agree to amend the Agreement in order to provide that the termination under Section 11(b) of the Agreement as to Barrington shall not affect the validity of the Agreement and that the suspension by the Company shall be on an interim basis until such later date as the Company may give notice to AGP.

 

Please execute a copy of this letter agreement indicating that the Agreement shall be amended.

 

  Sincerely yours,
   
  COCRYSTAL PHARMA, INC.

 

  By: /s/ James Martin
    James Martin
    Chief Financial Officer

 

 
 

 

Alliance Global Partners//A.G.P

March 20, 2019

Page 2

 

We hereby agree to the foregoing:

 

Alliance Global Partners//A.G.P

 

By: /s/ Thomas J. Higgins  
  Thomas J. Higgins  
  Managing Director, Investment Banking  

 

cc: Mr. Gary Wilcox (via email)  
  Michael D. Harris, Esq. (via email)